prasinezumab   Click here for help

GtoPdb Ligand ID: 13330

Synonyms: PRX002 | RG-7935 | RG7935 | RO-7046015 | RO7046015
Compound class: Antibody
Comment: Prasinezumab (RO7046015) is a monoclonal antibody that binds the C-terminus of neurotoxic (aggregated) forms of α-synuclein. It was designed to reduce the cell-to-cell spread of toxic α-synuclein aggregates in the brains of people with Parkinson's disease, as a disease-modifying therapeutic approach to slow the rate of neuronal damage and disease progression.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J et al.. (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Lancet, 390 (10103): 1664-1675. [PMID:28781108]
2. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A et al.. (2013)
Exenatide and the treatment of patients with Parkinson's disease.
J Clin Invest, 123 (6): 2730-6. [PMID:23728174]
3. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M et al.. (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
JAMA Neurol, 75 (10): 1206-1214. [PMID:29913017]
4. Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C et al.. (2024)
Trial of Lixisenatide in Early Parkinson's Disease.
N Engl J Med, 390 (13): 1176-1185. [PMID:38598572]
5. Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H et al.. (2024)
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Nat Med, 30 (4): 1096-1103. [PMID:38622249]
6. Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP et al.. (2022)
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
N Engl J Med, 387 (5): 421-432. [PMID:35921451]